Current Headlines

  1. Penn’s Drug For Rare Blood Disorder Snags FDA Orphan Status
    10/31/2014

    Penn Medicine announced that AMY-101, a drug developed at the institute, has been awarded Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) as treatment for the rare and deadly blood disorder, paroxysmal nocturnal hemoglobinuria (PNH).

  2. Boehringer Ingelheim, Lilly Revise Diabetes Alliance
    10/31/2014

    Boehringer Ingelheim and Eli Lilly have revised their Diabetes Alliance in an effort to enhance efficiency and focus on product launches.

  3. Bristol-Myers Squibb Acquires Option To Buy F-star Alpha, FS102 For HER2 Cancers
    10/31/2014

    Bristol-Myers Squibb Company (BMS) may opt to buy F-star Alpha and its lead HER2 oncology candidate, FS102. The exclusive option to acquire F-star Alpha and its assets was announced in a press release, which disclosed that the aggregate deal is worth $475 million.

  4. Takeda Licenses Mersana’s Fleximer-ADC Candidate For Onco-Targets
    10/31/2014

    Takeda’s Millennium Pharmaceuticals has licensed Mersana Therapeutics’ Fleximer- antibody-drug conjugate (ADC) candidate for oncology indications.

  5. TSRI’s MS Drug Also Shows Promise In Ulcerative Colitis
    10/30/2014

    The Scripps Research Institute (TSRI) reported that results from the Phase 2 study of RPC1063, a drug discovered at the Institute, show RPC1063’s potential in the treatment of ulcerative colitis (UC).

  6. Salk Scientists Identify Protein As HIV-1 Therapeutic Target
    10/30/2014

    A team of scientists from the Salk Institute for Biological Studies reported that they have identified a protein that could be exploited as HIV-1’s Achilles heel.

  7. GSK Expands Drug Research Partnership With Five Prime
    10/30/2014

    Five Prime Therapeutics, a clinical stage biotech firm, announced that its partner GlaxoSmithKline has extended their drug research collaboration in respiratory diseases for another year and a half.

  8. Cancer Innovation Coalition Seeks To Close Gap Between Development And Market
    10/30/2014

    The Cancer Innovation Coalition (CIC) convened its first national policy forum this week where researchers, government officials, and industry experts met to discuss methods of closing the gap between promising new therapies and cancer patients, Drug Discovery and Development (DDD) reports.

  9. PhosImmune, Pure MHC Collaborate To Develop New Cancer Immunotherapies
    10/29/2014

    Oncology biotech company PhosImmune has announced that it has entered into a license and collaboration agreement with Pure MHC, a subsidiary of PureProtein specializing in disease-specific target identification and drug discovery for cancer and other diseases.

  10. New Anti-Cancer Drug Shows Promising Results With Low Toxicity
    10/29/2014

    Researchers at the University of Chicago have reported ‘dramatic’ anti-cancer activity of a new drug, OTS964, which was able to completely eliminate aggressive human lung cancers transplanted into mice — and with minimal side effects.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.